Edition:
United States

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

11.38USD
16 Oct 2017
Change (% chg)

-- (--)
Prev Close
$11.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
64,803
52-wk High
$14.63
52-wk Low
$6.27

Latest Key Developments (Source: Significant Developments)

Karyopharm reports positive data from ongoing cancer drug study
Wednesday, 20 Sep 2017 07:00am EDT 

Sept 20 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm announces successful outcome from phase 2 portion of phase 2/3 seal study evaluating selinexor in patients with previously treated advanced dedifferentiated liposarcoma.Karyopharm Therapeutics - ‍phase 3 portion of 2/3 seal​ study commenced; expanded to include North America, Europe, expected to enroll up to 222 patients.Karyopharm Therapeutics Inc - ‍top-line of data expected by end of 2019 for 2/3 seal study​.Karyopharm Therapeutics - ‍FDA has confirmed its acceptance of proposed phase 3 seal study design, including PFS primary endpoint.  Full Article

Karyopharm Therapeutics Q2 loss per share $0.64
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm reports second quarter 2017 financial results and highlights recent progress.Q2 loss per share $0.64.Q2 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm Q1 loss per share $0.71
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm reports first quarter 2017 financial results and highlights recent progress.Q1 loss per share $0.71.Q1 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Karyopharm Therapeutics Inc :Karyopharm and Anivive Lifesciences sign exclusive global license agreement for Verdinexor for Animal Health Applications.Karyopharm Therapeutics Inc - Karyopharm to receive $1 million upfront payment.Karyopharm Therapeutics Inc - Karyopharm then eligible to receive up to $43.5 million in future milestones, plus royalties.  Full Article

Karyopharm Therapeutics announces pricing of public offering of common stock
Tuesday, 25 Apr 2017 09:22am EDT 

April 25 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm Therapeutics announces pricing of public offering of common stock.Karyopharm Therapeutics -pricing of a registered underwritten public offering of 3.9 million shares of common stock at price to public of $10.25 per share.  Full Article

Karyopharm Therapeutics announces proposed public offering of common stock
Monday, 24 Apr 2017 04:01pm EDT 

April 24 (Reuters) - Karyopharm Therapeutics Inc : :Karyopharm Therapeutics announces proposed public offering of common stock.Karyopharm Therapeutics Inc says commencing a registered underwritten public offering of $40 million in shares of its common stock.Karyopharm Therapeutics - intends to use proceeds of offering in part to support continued clinical development of selinexor in multiple myeloma.  Full Article

Karyopharm reports interim Phase 2b SADAL data
Tuesday, 4 Apr 2017 01:00pm EDT 

Karyopharm Therapeutics Inc : Karyopharm reports interim Phase 2b SADAL data at the 2017 American Association for Cancer Research annual meeting . 28.6% overall response rate demonstrated with a median duration of greater than seven months . Top-line data from SADAL study expected in mid-2018 . Should data confirm current results, plan to apply for accelerated approval for treatment of relapsed / refractory DLBCL . Amending SADAL study protocol to become single-arm study focusing solely on single-agent selinexor dosed at 60mg twice weekly . SADAL study being amended to reduce 14-week treatment-free period to 8 weeks in patients who achieved at least PR on most recent therapy . Company plans to enroll up to an additional 90 patients to new 60mg single-arm cohort .Patients who were refractory or did not achieve at least a PR on their prior therapy in SADAL study to continue 14-week treatment-free period.  Full Article

Karyopharm and Medidata expand clinical trial partnership
Tuesday, 4 Apr 2017 08:30am EDT 

Karyopharm Therapeutics Inc : Karyopharm and medidata expand clinical trial partnership .Karyopharm -expanded partnership to bring machine-learning technology and targeted risk-based monitoring techniques to clinical oncology trials.  Full Article

Karyopharm says CFO Justin Renz resigned
Monday, 3 Apr 2017 04:05pm EDT 

Karyopharm Therapeutics Inc : Says CFO Justin Renz resigned . Karyopharm announces management change . Karyopharm Therapeutics Inc - Renz will continue to serve company in an advisory capacity in order to ensure a smooth transition . Karyopharm Therapeutics Inc - Karyopharm has begun a search process for selection and appointment of a new chief financial officer .Karyopharm Therapeutics - in interim, Michael Todisco, who has served as company's vice president, finance, will lead its internal finance function.  Full Article

U.S. FDA Division of Hematology products lifts partial clinical hold on Selinexor clinical trials
Thursday, 30 Mar 2017 07:00am EDT 

Karyopharm Therapeutics Inc : U.S. FDA Division of Hematology products lifts partial clinical hold on Karyopharm’S Selinexor clinical trials . Timelines for ongoing and planned studies expected to remain materially unchanged . Recruitment resumes across all Selinexor trials in hematological malignancies .Investigator sponsored trials in hematologic malignancies with Selinexor may resume accruing patients.  Full Article

BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

* Karyopharm and Ono Pharmaceutical Co. Ltd. sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia